Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer

Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Shamit K. Dutta, Debabrata Mukhopadhyay, Frank A Sinicrope

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-Apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1.Upregulation ofMCL-1 wasmediated byMEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylationmimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increasedMCL-1 protein turnover, respectively. MEK/ ERK inhibition by cobimetinib suppressed MCL-1 expression/ phosphorylation and induced proapoptotic BIMto a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The smallmolecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction ofMCL-1 with proapoptoticBAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediatedMEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonismcombined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs.

Original languageEnglish (US)
Pages (from-to)3015-3027
Number of pages13
JournalMolecular Cancer Therapeutics
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Colorectal Neoplasms
Up-Regulation
Apoptosis
Mitogen-Activated Protein Kinase Kinases
Phosphorylation
Small Interfering RNA
Cell Line
Treatment Failure
Heterografts
Colonic Neoplasms
GDC-0973
Mutation
Therapeutics
Genes
Proteins
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. / Kawakami, Hisato; Huang, Shengbing; Pal, Krishnendu; Dutta, Shamit K.; Mukhopadhyay, Debabrata; Sinicrope, Frank A.

In: Molecular Cancer Therapeutics, Vol. 15, No. 12, 01.12.2016, p. 3015-3027.

Research output: Contribution to journalArticle

@article{d75bb7124d4e4b5bbe065cf8dc049b46,
title = "Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer",
abstract = "Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-Apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1.Upregulation ofMCL-1 wasmediated byMEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylationmimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increasedMCL-1 protein turnover, respectively. MEK/ ERK inhibition by cobimetinib suppressed MCL-1 expression/ phosphorylation and induced proapoptotic BIMto a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The smallmolecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction ofMCL-1 with proapoptoticBAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediatedMEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonismcombined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs.",
author = "Hisato Kawakami and Shengbing Huang and Krishnendu Pal and Dutta, {Shamit K.} and Debabrata Mukhopadhyay and Sinicrope, {Frank A}",
year = "2016",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0017",
language = "English (US)",
volume = "15",
pages = "3015--3027",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer

AU - Kawakami, Hisato

AU - Huang, Shengbing

AU - Pal, Krishnendu

AU - Dutta, Shamit K.

AU - Mukhopadhyay, Debabrata

AU - Sinicrope, Frank A

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-Apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1.Upregulation ofMCL-1 wasmediated byMEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylationmimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increasedMCL-1 protein turnover, respectively. MEK/ ERK inhibition by cobimetinib suppressed MCL-1 expression/ phosphorylation and induced proapoptotic BIMto a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The smallmolecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction ofMCL-1 with proapoptoticBAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediatedMEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonismcombined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs.

AB - Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-Apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1.Upregulation ofMCL-1 wasmediated byMEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylationmimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increasedMCL-1 protein turnover, respectively. MEK/ ERK inhibition by cobimetinib suppressed MCL-1 expression/ phosphorylation and induced proapoptotic BIMto a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The smallmolecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction ofMCL-1 with proapoptoticBAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediatedMEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonismcombined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs.

UR - http://www.scopus.com/inward/record.url?scp=85008392584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008392584&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0017

DO - 10.1158/1535-7163.MCT-16-0017

M3 - Article

VL - 15

SP - 3015

EP - 3027

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -